Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dovitinib
- Development stage
- Phase 3
- Lead developer
- Allarity Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dovitinib is an orally bioavailable, small-molecule multi-tyrosine kinase inhibitor (TKI) that targets several receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis. Its primary targets include fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), and platelet-derived growth factor receptors (PDGFR). Originally developed by Novartis, dovitinib was licensed to Allarity Therapeutics (formerly Oncology Venture) in 2018. Allarity sought to develop the drug using its Drug Response Predictor (DRP) companion diagnostic to identify patients most likely to respond, particularly in renal cell carcinoma and breast cancer. However, following regulatory hurdles and a material breach of contract, Novartis terminated the license in January 2024, and all rights reverted to Novartis. The drug has also been investigated for pediatric cancers through a sub-licensing agreement with Oncoheroes Biosciences.
- Other names
- dovitinib lactatedovitinib-DRP
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on dovitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dovitinib.